Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.
You may also be interested in...
No negative actions have been taken in the US FDA’s oncology review divisions, but vague diversity guidance continues to raise concerns.
The FDA commissioner says that improving health disparities would fix the lack of diversity in clinical trials.
Project Site Selector will allow FDA Oncology Center of Excellence staff to discuss site selection process with industry and potentially help improve clinical trial diversity efforts.